Citius Oncology, Inc. (CTOR) — Net Asset Quality Index
Citius Oncology, Inc. (CTOR) has a Net Asset Quality Index of 35.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $100.70 Million minus total liabilities of $65.43 Million yields net assets of $35.27 Million. A higher index indicates a stronger, lower-leverage balance sheet. See CTOR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Citius Oncology, Inc. Net Asset Quality Index Over Time (2022–2025)
This chart shows how Citius Oncology, Inc.'s Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of March 2026, the index stands at 35.0%, representing net assets of $35.27 Million against total assets of $100.70 Million USD. Explore Citius Oncology, Inc. operating cash flow efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Citius Oncology, Inc. (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for Citius Oncology, Inc. from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Citius Oncology, Inc. (CTOR) total market value.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 44.4% | $44.87 Million | $100.94 Million | $56.08 Million | ▼ -10.2 pp |
| 2024 | 54.7% | $46.14 Million | $84.37 Million | $38.23 Million | ▲ +1.2 pp |
| 2023 | 53.5% | $25.54 Million | $47.73 Million | $22.20 Million | ▼ -31.5 pp |
| 2022 | 85.0% | $36.27 Million | $42.69 Million | $6.42 Million | — |